- Home
- CANF vs PYPD Comparison
CANF vs PYPD Comparison
Compare CANF & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | PYPD |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 77.4M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CANF | PYPD |
|---|---|---|
| Price | $3.42 | $4.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $9,750.00 | $12.00 |
| AVG Volume (30 Days) | ★ 609.7K | 48.8K |
| Earning Date | 03-27-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | $290,391.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $2.30 |
| 52 Week High | $10.40 | $5.12 |
Technical Indicators
Market Signals| Indicator | CANF | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 48.00 |
| Support Level | $0.60 | $4.26 |
| Resistance Level | $4.74 | $4.38 |
| Average True Range (ATR) | 0.64 | 0.18 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 1.23 | 36.80 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.